Professional Documents
Culture Documents
中 国 医 药 市 场 指 南
Written by:
China Office
Suite 17D, Building B, Oriental Kenzo Plaza
48 Dongzhimenwai Dajie, Dongcheng District, Beijing 100027, China
Tel: +86 10 84476010/11 Fax: +86 10 84476110
E-mail: info@pharmachinaonline.com
companies, CROs, consulting companies and investment banking firms active in China.
James Shen was educated in China, Europe and the USA at university and postgraduate
levels, and received an MBA from the University of Exeter (UK) in 1990.
He is now based in Princeton, New Jersey with frequent visits to China and Europe. He
continues to be active in strategic consulting with multinational pharmaceutical
companies at headquarter and regional head office levels.
PREFACE
Despite the enormous business opportunities and growth prospects offered by China’s
healthcare sector, I’ve witnessed and experienced countless regulatory and business
environmental changes, which has frequently caused painful business difficulties,
frustrations and downfalls, in my past 24 years of work in the sector as a consultant,
manager and entrepreneur.
The ever-changing legal and market environments in China healthcare present the single
biggest challenge to companies and executives operating in the sector. Naturally, many
operational level issues and problems in the country also pose significant dangers to
successful businesses.
Despite these challenges and difficulties, the Chinese pharmaceutical industry and
market have achieved remarkable growth in the past two decades. The sector is generally
developing towards a positive direction in the sense that it continues to grow steadily, its
regulatory regime has become increasingly compatible with international standards with
improving transparency, once rampant corruption is being tackled, its ongoing
consolidation will eventually help establish order and stability, and the country’s new
healthcare reform will ultimately led to a more stable and healthier market environment.
There are success stories from all categories of players, whether they are foreign or local,
large or small, newcomer or established, private or state-owned. However, to be one of
the success stories require a thorough understanding of the sector, ability to face and
tackle challenges, flexibility to deal with changes, and skills to maneuver through
complex situations.
It has been my wish to put my experience and observation in the past 24 years operating
in almost every aspect of China’s pharmaceutical business into a publication, which will
serve as a one-stop reference to anyone seeking to enter or operating in the Chinese
pharmaceutical market. As of our 2007 edition, we have been adding a rising number of
commentaries and contributions from many other leading pharma industry executives
and experts.
Packed with hard-to-find current data and the author’s expert knowledge from years of
hard-earned experience in the industry, its comprehensiveness, practicality, insight,
reliable data and analysis, and up-to-date information, are the features which set this the
guide apart from other publications with similar titles.
This Guide is written based on my past experience, interviews with relevant industry
experts and government officials, articles from Pharma China, information obtained
from or published by Chinese government agencies, information obtained from or
published by independent pharmaceutical industry associations, reliable data and
information released exclusively to WiCON for publication from various reputable
market research and consulting firms, information from other trustworthy trade journals
and newspapers, related information found on the internet, and a large in-house
TABLE OF CONTENTS
.........................................................................................................................................................285
3.8 State Administration of Traditional Chinese Medicine (SATCM)...........................................285
3.9 National Population and Family Planning Commission (NPFPC)..........................................286
7.3 Market Segments for New Drugs and Generic Drugs............................................................. 552
7.4 Analysis of Leading Foreign Drug Companies in China ........................................................ 552
7.5 Analysis of Leading Foreign Drug Products in China ............................................................ 553
7.6 Future Trends and Outlook ..................................................................................................... 553
CHAPTER VI-5 SALES & MARKETING OF OTC DRUG PRODUCTS IN CITIES 588
5.1 Channels of OTC Drug Sales.................................................................................................. 588
5.2 Process and Key Components of OTC Drug Sales ................................................................. 589
5.3 Key Factors in OTC Drug Sales.............................................................................................. 590
LIST OF TABLES
Table 2.1 Overall Chinese Drug Market Size and Growth 2001-08 ................................78
Table 2.2 Chinese Drug Market Size by Major Segments 2001-2008.............................78
Table 2.3 Chinese Drug Market Shares by Sub-segments 2003-2008.............................79
Table 2.4 Growth in the Number of Pharmaceutical Businesses in China ......................80
Table 2.5 Growth in Output Value of the Chinese Pharmaceutical Industry ...................82
Table 2.6 Growth in the Chinese Pharmaceutical Industry Revenues .............................83
Table 2.7 Growth of the Chinese Pharmaceutical Industry’s Net Profits 2007-2009 ......84
Table 2.8 Chinese pharmaceutical industry performance in 2009 (NDRC) ....................85
Table 2.9 Revenues and Profits of the Chinese Pharmaceutical Industry In 2009...........86
Table 2.10 Distributor Sales of Pharma Related Products in China 2000-2009 ..............86
Table 2.11 Distributor Sales of Pharmaceutical Chemicals in China...............................87
Table 2.12 Distributor Sales of Formulated TCMs in China ...........................................87
Table 2.13 Distribution of Pharma Industry Sales by Sectors and Ownership in 2009 ...89
Table 2.14 Distribution of Pharma Industry Profits by Sectors and Ownership in 2009.89
Table 2.15 Leading Ten Chinese Pharma Companies in 2008 by Sales ..........................91
Table 2.16 MNC Subsidiaries/JVs in the Leading 100 Chinese Pharma Cos in 2008.....92
Table 2.15 New Vaccine Products of Selected Chinese Biotech Cos in 2008/2009 ......103
Table 2.17 First 10 Sino-Foreign Pharmaceutical Joint Ventures in China....................134
Table 2.18 Foreign Investment in the Chinese Pharmaceutical Industry.......................134
Table 2.19 Pharma foreign investments in China between 2000 and 2006 ...................135
Table 2.20 The World’s Leading Pharmaceutical Companies in China .........................136
Table 2.21 Top 10 MNC Companies by Hospital Drug Sales in 2009 ..........................139
Table 2.22 Chinese Retail Pharmacy Market Segmentation 2005-2009........................206
Table 2.23 Chinese Retail Market for Western Medicines by TCs 12/2009 ..................206
Table 2.24 Growth of Third Terminal and Community Markets 2003-08 .....................213
Table 2.25 Chinese Vaccine Market 2006-2009.............................................................214
Table 2.26 Market Shares of Chinese and Foreign Vaccines Companies by Volume ....214
Table 2.27 Market shares of Chinese and foreign vaccines companies by value ..........214
Table 2.28 Estimated Size and Growth of Chinese Retail Pharmacy Market 2002-2009
........................................................................................................................................217
Table 2.29 Growth of the Chinese API/Bulk Drug Sector 2002-2009...........................226
Table 2.30 Output/Export Volume Change of Major Classes of APIs in 1H/08 ............228
Table 2.31 Export Sales Growth of Major Categories of APIs in 2008 .........................228
Table 2.32 Export Sales of Major API Products in 2008 ............................................... 229
Table 2.33 Leading API export products in 2009 .......................................................... 229
Table 2.34 Foreign Trade of Medicines and Health Products in 2009 .......................... 238
Table 2.35 Foreign Trade of Western Medicines in 2009 .............................................. 238
Table 2.36 Major Categories of Western Medicine Import 2003-2009 ......................... 238
Table 2.37 Major Categories of Western Medicines Export in 2003-2009.................... 239
Table 2.38 Leading Ten Western Medicine Importers in 2009 ...................................... 240
Table 2.39 Leading Chinese import origins of drug products in 2009 .......................... 240
Table 2.40 Leading Ten Export Markets for Chinese-made WMs in 2009 ................... 242
Table 2.41 Top ten Chinese exporters of WMs in 2009................................................. 242
Table 2.42 Leading 20 Exporters of WM Formulations in 2009 ................................... 243
Table 2.43 Leading 20 Chinese API exporters in 2009 ................................................. 243
Table 2.44 Leading WM formulation export products in 2009 ..................................... 244
Table 3.1 Drug Approvals Issued by SFDA 2007-2009 ................................................ 252
Table 3.2 China’s Drug Approvals by Therapeutic Classes 2007-2009 ........................ 252
Table 3.3 Breakdown of all drug evaluation cases in 2009 ........................................... 253
Table 3.4 Breakdown of all new submissions in 2009................................................... 253
Table 3.5 Breakdown of all supplemental applications in 2009 .................................... 254
Table 4.1 Improvement of Medical Provision in China................................................. 400
Table 4.2 Comparisons of Healthcare Provision by China vs. Other Countries(1) ....... 400
Table 4.3 Comparisons of Healthcare Provision by China vs. Other Countries (2) ...... 401
Table 4.4 Birth, Death and Population Natural Growth Rate ........................................ 402
Table 4.5 Rising Life Expectancy of the Chinese Population ....................................... 403
Table 4.6 Composition of the Chinese Population by Urban/Rural Division and Sex .. 403
Table 4.7 Composition of the Chinese Population by Age ............................................ 404
Table 4.8 Composition of the Chinese Population by Education .................................. 405
Table 4.9 Medical Institutions by Specialties and Affiliations ...................................... 407
Table 4.10 Inpatient Beds of Medical Institutions by Specialties and Affiliations........ 408
Table 4.11 Share of Non-Profit and For-Profit Medical Institutions in 2009 ................ 409
Table 4.12 Share of Medical Institutions by Ownership in 2009 .................................. 409
Table 4.13 Share of Inpatient Beds of Medical Institutions in 2009 ............................. 410
Table 4.14 Share of Inpatient Beds of Medical Institutions in 2009 ............................. 410
Table 4.15 Number of Medical Institutions by Grade in 2009 ...................................... 411
Table 4.16 Regional Population Distribution in China 1990-2008................................ 412
Table 4.17 Regional Distribution of Medical Institutions and Inpatient Beds in 2009 . 413
Table 5.25 Leading MNC drug suppliers to Chinese hospitals in 2009 (CPA) ............. 523
Table 5.26 Leading 15 Pharma Suppliers by Hospital Sales in 1H/2009 (CPA) ........... 523
Table 5.27 Top 10 Therapeutic Classes in 2009 by Hospital Drug Purchases............... 523
Table 5.28 Top Ten Therapeutic Classes in 2008 by Hospital Drug Purchases............. 524
Table 5.29 Drug Purchases by Representative Hospitals 2005-2009 Unit: CNY Mln 525
Table 5.30 Leading 20 products by hospital purchase value in 2008-2009................... 526
Table 5.31 Changing Hospital Drug Consumption Patterns 1999 – 2009 ..................... 527
Table 5.32 Chinese Retail Market for Western Medicines by TCs 2008-2009.............. 531
Table 5.33 Leading Ten Chinese Retail Pharmacy Chains in 2009 by Sales................. 532
Table 5.34 Top 10 Chinese Retail Pharmacy Chains in 2008 by Stores ........................ 533
Table 5.35 Leading 10 Retail Pharmacy Chains by Revenues in 2009 ......................... 534
Table 5.36 Chinese OTC Drug Sales by Therapeutic Classes 2005-2009..................... 538
Table 5.37 Leading Chinese OTC Brands (Chemical Drugs) in 2009........................... 538
Table 5.38 Leading Chinese OTC Companies in 2009.................................................. 539
Table 5.39 Sales of Pharmaceutical Chemical Finished Products by Regions in 2004 . 542
Table 5.40 Hospital Drug Markets of Key Chinese Cities/Regions in MAT 3Q/2009.. 543
Table 5.41 Shares of 16 Major Chinese Regional Markets in 2006 .............................. 544
Table 5.42 Regional Market Shares for Imported Drug Products in 2006 .................... 545
Table 5.43 Regional Market Shares for JV-made Drug Products in 2006 ..................... 545
Table 5.44 Regional Market Shares for Local Drug Products in 2006.......................... 546
Table 5.45 Market Share of Imported Drugs in Ten Major Chinese Cities in 2Q, 1995548
Table 5.46 Hospital Market Shares of Local, FIE and Foreign Companies 2002-08 .... 548
Table 5.47 Hospital Market Shares of Local, JV and Imported Drugs 2006-2009........ 550
Table 5.48 Market Shares of Local & Foreign Cos in Retail Drug Sales 2004-06........ 551
Table 6.1 Number of Cities Accounting for 90% of the Market.................................... 579
Table 6.2 Chinese Pharmaceutical Distributor Sales in 2007 ........................................ 596
Table 6.3 Chinese Pharma Distributors with the Highest Growth in 2008.................... 598
Table 6.4 Leading 20 Chinese Pharmaceutical Distributors in 2008............................. 598
Table 7.1 Comparison of Diabetes Patient HbA1c levels at CHCs and Tier III Hospitals
........................................................................................................................................ 641
Table 7.2 Survey of MNCs over Impacts of Chinese Healthcare Reform..................... 649
Table 10.1 Pfizer’s hospital drug sales 2006-2009 ........................................................ 832
Table 10.2 AstraZeneca’s hospital drug sales 2006-2009 .............................................. 840
Table 10.3 AstraZeneca’s hospital drug sales 2006-2009 .............................................. 846
Table 10.4 Novartis’s hospital drug sales 2006-2009 .................................................... 856
LIST OF CHARTS
Chart 2.1 Output Value Growth of the Chinese Pharmaceutical Industry ....................... 82
Chart 2.2 Revenue Growth Rates of the Chinese Pharmaceutical Industry 2001-2009 .. 83
Chart 2.3 Segmentation of Chinese Pharma Industry Revenues in 2009* ...................... 84
Chart 2.4 Segmentation of Chinese Pharma Industry Profits in 2009* ........................... 84
Chart 2.5 Sales Margin Trend of the Chinese Pharma Industry 1997-2009 .................... 85
Chart 2.6 Distribution of Pharma Industry Sales by Ownership Types in 2009.............. 89
Chart 2.7 Distribution of Pharma Industry Profits by Ownership Types in 2009............ 90
Chart 2.8 Application Procedures Of APP..................................................................... 166
Chart 2.9 Flowchart – Revocation Procedures Of APP ................................................. 167
Chart 2.10 Re-examination Procedures Of APP ............................................................ 169
Chart 2.11 Infringement Settlement Procedures of APP................................................ 170
Chart 2.12 Size and Growth of Chinese Retail Pharmacy Market 2000-2009 .............. 205
Chart 3.1 Administrative Structure of Food and Drug Regulation in China ................. 265
Chart 3.2 Functional Departments of the SFDA............................................................ 272
Chart 3.3 Application and Approval Procedures for Clinical Trials .............................. 320
Chart 3.4 Application and approval procedure for imported drugs (1).......................... 323
Chart 3.5 Application and approval procedure for imported drugs (2).......................... 323
Chart 3.6 Supplemental Application and Approval Procedure for Imported Drugs (1) 324
Chart 3.7 Supplemental Application and Approval Procedure for Imported Drugs (2) 325
Chart 5.1 Growth of Per Capita Healthcare Expenditures in China 1990-2009............ 483
Chart 5.2 Core Product Sales Composition of Chinese Retail Pharmacies in 2007-09. 531
Chart 6.1 Structure of the Chinese Pharma Distribution System in the Old Days ........ 558
Chart 6.2 Approval Process of Hospital Drug Purchase ................................................ 575
Chart 6.3 Hospital Market Potential Assessment Process ............................................. 578
Chart 6.4 Type of Clinical Trials Conducted in China in 2007...................................... 582
Chart 6.4 Pharmaceutical Distribution Channels in the Urban Areas............................ 601
Chart 6.5 Pharmaceutical Distribution through Retail Pharmacies ............................... 602
Chart 6.6 Pharmaceutical Distribution in Sub-urban and Rural Areas .......................... 603
Chart 6.7 Dominant distribution models used by MNCs in China ................................ 611
Chart 7.1 Average number of patients seen per condition, per week............................. 639
Chart 7.2 Prescribing habits of physicians at Level III hospitals and CHCs................. 641
Chart 7.3 Breadth and depth of hypertensive prescriptions at CHCs ............................ 642
Chart 7.4 Expected Changes to MNC Marketing Strategics after Healthcare Reform.. 651
Chart 7.5 Expected Changes to MNC Marketing Strategics after Healthcare Reform.. 652
TABLE OF ABBREVIATIONS
ADR – Adverse Drug Reaction NBS – National Bureau of Statistics
API – Active Pharmaceutical Ingredients NCGHSR - National Coordination Group
APP – Administrative Protection of for Healthcare System Reform
Pharmaceuticals NDRC – National Development and
AmCham – American Chamber of Reform Commission
Commerce NPFPC – National Population and Family
CCCIEMHP – China Chamber of Planning Commission
Commerce for Import & Export of OECD – Organization for Economic
Medicines and Health Products Co-operation and Development
CNCM – China National Corporation of OTC – Over The Counter
Medicines QA – Quality Assurance
CAPC – China Association of PRC –People’s Republic of China
Pharmaceutical Commerce
R&D – Research and Development
CNY – Chinese Yuan
RDPAC - R&D-based Pharmaceutical
CRO – Contract Research Organization Association Committee
ED – Erectile Dysfunction SATCM – State Administration of
FDI – Foreign Direct Investment Traditional Chinese Medicine and
FIEs – Foreign Invested Enterprises Medicines
GCP – Good Clinical Practices SDA – State Drug Administration
GDP – Gross Domestic Products SFDA – State Food and Drug
Administration
GLP – Good Laboratory Practices
SIPO – State Intellectual Property Office
GMP – Good Manufacturing Practices
SMEI – Southern Medicine Economic
GSP – Good Sales Practices
Institute
IFPMA – International Federation of
SOE – State Owed Enterprise
Pharmaceutical Manufacturer Associations
SPAC – State Pharmaceutical Admini-
JV – Joint Venture
stration of China
M&A – Merger and Acquisition
STD – Sexually Transmitted Disease
MIIT – Ministry of Industry and
TC – Therapeutic Class
Information Technology
TCM – Traditional Chinese Medicine
MOC – Ministry of Commerce
USFDA – US Food and Drug
MOF – Ministry of Finance
Administration
MOH – Ministry of Health
USTR – US Trade Representative
MoHRSS – Ministry of Human
VAT – Value Added Tax
Resources and Social Security
WM – Western medicine
MNC – Multinational pharmaceutical
companies (in the context of this guide) WHO – World Health Organization
MR – Medical Representative WTO – World Trade Organization
James J. Shen
China’s economy is already the third largest in the world. Its foreign exchange reserve
stands second to none. In the next three years, China’s GDP is expected to grow between
7-9% per annum, while the overall compound annual growth rate of the pharmaceutical
market (2009-2013) is projected to be 24%.
Sustained economic development is foundational to growing healthcare expenditures; in
China, healthcare spending CAGR (2006-2011) is expected to surge to 20%. Rising
levels of disposable income, meanwhile, are laying the groundwork for higher
out-of-pocket expenditures for healthcare and pharmaceutical products.
Continuous double-digit growth in the past two decades has convinced even the most
conservative industry analysts to offer optimistic views about the future of the Chinese
pharmaceutical market.
Recap of Chinese pharmaceutical sector last year
Despite the global financial crisis and economic slowdown, the Chinese pharmaceutical
sector maintained its high growth in 2009. The uninterrupted growth was driven by
improved order of the Chinese pharmaceutical market place, exits of small and irregular
competitors, relatively more stability in drug regulation, increased government
healthcare funding and surging market demands.
Output value and sales value of the Chinese pharmaceutical industry rose 21.02% and
21.19% respectively, reaching CNY 940,305 million and 896,589 million last year,
according to the National Development and Reform Commission (NDRC). Affected by
the falling export sales, the 2009 growth rates were 2.6 and 1.4 percentage points lower
respectively than the same for 2008.
The output value of the chemical drug sub-industry rose 16.80% to 483,183 million in
2009, while that of biological products rose 23.97% to 211,168 million. The growth rates
of both sub-industries were substantially lower than those in 2008.
Also noteworthy is the much higher growth rates of new product output for the
pharmaceutical industry and chemical drug sub-industry at 28.38% and 25.30%
respectively, indicating a shift to new generations of drug products.
The Chinese hospital market surged 27% in MAT 3Q/2009, while the Chinese retail
market and vaccine markets grew around 15% last year. In the meantime, the growth of
the Chinese OTC market continued to be slower than other market segments at nearly
10%.
Many leading Chinese companies, including Hengrui Pharma (+57%), Shanghai Pharma
(+100%) and Fosun Pharma (+250%), reported sharp profit growth last year, suggesting
improving margins for large pharmaceutical companies. Industry-wide, however, the
profit growth is expected to have been lower than that in 2008.
China Pharmaceutical Guide 2010 (5th Edition)
To achieve its goal, the Chinese government has adopted industrial and regulatory
policies that favor research-based multinationals and large domestic enterprises, and at
the same time, it has improved market access for foreign companies, strengthened IP
environment to foster innovation and, most recently, cleaned up the country’s
marketplace to ensure success of larger and innovative companies.
Because of this, China has won increasing trust and confidence from foreign companies,
most notably from R&D-based multinationals, who are boosting their investments in the
country not only to expand manufacturing and marketing operations, but also to move
some of their critical business operations and to transfer core technologies to the
country.
Today, China is well on its way to develop its pharmaceutical industry side by side with
the research-based multinational pharmaceutical companies. With the ongoing
restructure of the global pharmaceutical industry in the backdrop, the fate of the Chinese
pharmaceutical industry and those of R&D-based MNCs are increasingly linked together.
As this bond grows stronger and deeper, it becomes a path of no return for both sides.
China will be, as its long term policy, committed to supporting new drug innovation as
well as growth and development of research-based multinational companies in the
country, while, at the same time, attempting to foster the rise of its own large and
innovative companies at the same time.
On the other hand, China faces the daunting challenge of securing the essential
healthcare needs of its entire people. As the country’s economy continues to grow, the
need for new medicines and high quality healthcare will also rise. While large domestic
companies are best-positioned to fulfill the essential healthcare needs of the nation in the
short- and medium-term, innovative MNCs are certainly better -suited for the task of
satisfying higher level demands.
Despite short term regulatory corrections, administrative changes or healthcare reform
uncertainties, the long term direction and present development path for China’s
pharmaceutical sector are unlikely to be altered in any significant way.
MNCs in search of higher and broader growth in China
In spite of the turbulent market and regulatory environment, innovative multinational
pharmaceutical companies (MNCs) have managed to establish a solid foothold and
accumulated their business strength in China in the past decade.
During the period, MNCs have consolidated their bases and organizations in the country,
gained absolute control in their joint ventures, expanded sales and marketing networks,
improved on IPR awareness and enforcement, quietly increased their influence over the
Chinese government and its policies, and most importantly, successfully fostered an
industrial and market environment that is now relatively more friendly to them.
Big pharma companies fared well in China again in 2009. The country is already one of
the largest overseas markets for most MNC companies and it is on the way to become
the largest for many in the near future.
Pfizer reported overall growth of between 25% and 28% in China last year, while that in
its other emerging markets was only 12% to 14%. Bayer Healthcare and Roche also had
growth higher than 20%. All three want higher growth in the near future.
With global pharmaceutical industry restructure accelerated, most MNCs stepped up
their China business last year through strategic adjustments and additional investments.
Besides, a score of companies including Roche and Bayer Healthcare upgraded their
China business units to facilitate higher business priority of and top management
attention on China. Roche even moved its Asia Pacific headquarters to China in late
2009 and Bayer said it may even move the HQ of a global business unit to China in the
foreseeable future.
MNCs are resorting to a wider range of new and existing strategies to fulfill their
growing ambitions in China including:
Horizontal business diversification: In addition to the traditional urban hospital and
retail pharmacy markets, MNCs are now diversifying horizontally into a range of other
business areas including vaccines, generic drugs and consumer healthcare products.
They are also broadening their business activities in China from mainly local
manufacturing and sales to R&D, sourcing, global logistic chain and
licensing/partnerships.
Vertical market expansion: Eyeing opportunities and market expansion brought by
China’s healthcare reform, MNCs are also working hard to penetrate into lower tier
cities and the urban community healthcare market.
M&As, JVs and licensing deals: Although many MNCs were actively looking for
acquisition targets in China, the outcome was meager in 2009 with only one such deal
made by Novartis to take over Chinese vaccine company Zhejiang Tianyuan Biopharma.
However, MNCs were more successful with joint venture deals – GSK concluded two
such deals in the vaccine sector, while Sanofi Aventis formed a new consumer healthcare
JV.
New product launches: Most MNC companies announced plans in recent years to boost
their new product launches in China to help drive new drug sales growth, and the
strengthening R&D capabilities of MNCs in China will further support this trend.
R&D outsourcing market grows at breakneck speed
There are drastically different estimates of the Chinese CRO market size at present, but
everyone agrees that there was phenomenon growth for the country’s R&D outsourcing
in the past few years and the future is bright with highly promising prospects.
Leading companies in this sector have typically recorded triple-digit growth and are
expanding in both their sales and business scope at astounding speed in the past few
years. It is widely expected that strong financial support from venture capitalists,
investors and the stock market will lead to fast expansion of the major players and the
sector as a whole.
Despite its huge potential, the further growth of the Chinese pharmaceutical R&D
In conclusion …
Despite the anticipated growth, we believe that the future outlook of the Chinese
pharmaceutical industry in the near future will continue to be heavily influenced by new
government policies in areas such as healthcare reform, drug pricing, drug registration,
basic medical insurance and healthcare administration.
Disputes and debates among stakeholders over the Chinese healthcare reform will persist
even after the release of the final official healthcare reform plan and the process of
reform has just started.
In the next three years, varying regional policies, local protectionism and characteristic
experiments will almost certainly result in a more fragmented and chaotic healthcare
marketplace. Pharmaceutical companies need to be vigilant, prudent and flexible to
navigate through troubled waters.
As the importance of China’s pharmaceutical industry grows and its bond with the world
fortifies, its future fate will no longer be isolated, but will instead be increasingly
intertwined with the global pharmaceutical marketplace.